MDM2 and neoplasm: MDM2 amplification may activate the bypass signaling pathways, inhibit tumor cell apoptosis, promote the epithelial to mesenchymal transition (EMT) process and tumor angiogenesis and contribute to primary resistance to EGFR-TKIs (Hou et al. 2019b).